Kyle P. Gribbin

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Rosalie C. Sears · 2 shared papers, 2026 · strength 0.49
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
   • Paper IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pa… DOI 10.1158/2326-6066.cir-25-1612↗
2. Katelyn T. Byrne · 2 shared papers, 2026 · strength 0.49
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
   • Paper IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pa… DOI 10.1158/2326-6066.cir-25-1612↗
3. Charles D. Lopez · 2 shared papers, 2026 · strength 0.49
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
   • Paper IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pa… DOI 10.1158/2326-6066.cir-25-1612↗
4. Aaron J. Grossberg · 1 shared paper, 2026 · strength 0.26
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
5. Jennifer M. Finan · 1 shared paper, 2026 · strength 0.26
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
6. Adel Kardosh · 1 shared paper, 2026 · strength 0.26
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
7. Jonathan Robert Brody · 1 shared paper, 2026 · strength 0.26
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
8. Teresa A Zimmers · 1 shared paper, 2026 · strength 0.26
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
9. Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.26
   • Paper Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for cli… DOI 10.1016/j.canlet.2026.218864↗
10. Lisa M. Coussens · 1 shared paper, 2026 · strength 0.23
    • Paper IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pa… DOI 10.1158/2326-6066.cir-25-1612↗
11. Gordon Brent Mills · 1 shared paper, 2026 · strength 0.23
    • Paper IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pa… DOI 10.1158/2326-6066.cir-25-1612↗
12. Katie E. Blise · 1 shared paper, 2026 · strength 0.23
    • Paper IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pa… DOI 10.1158/2326-6066.cir-25-1612↗
13. Zheng Xia · 1 shared paper, 2026 · strength 0.23
    • Paper IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pa… DOI 10.1158/2326-6066.cir-25-1612↗
14. Canping Chen · 1 shared paper, 2026 · strength 0.23
    • Paper IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pa… DOI 10.1158/2326-6066.cir-25-1612↗
15. Mara H. Sherman · 1 shared paper, 2026 · strength 0.23
    • Paper IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pa… DOI 10.1158/2326-6066.cir-25-1612↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.